UB Paderborn / Katalog / Suche / in CDI

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

The New England journal of medicine, 2017-10, Vol.377 (14), p.1345-1356

2017

Volltextzugriff (PDF)

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

European journal of cancer (1990), 2015-09, Vol.51, p.S664-S665

2015

Volltextzugriff (PDF)

1029TiP Phase II trial of pembrolizumab (pembro) and brentuximab vedotin (BV) in patients with metastatic solid malignancies after progression on prior programmed cell death protein (PD)-1 inhibitors (SGN35-033)

Annals of oncology, 2021-09, Vol.32, p.S862-S862

2021

Volltextzugriff (PDF)

1116P Real-world clinical outcomes with pembrolizumab (pembro) for treatment of advanced melanoma: Evidence from the United States community oncology setting

Annals of oncology, 2020-09, Vol.31, p.S752-S752

2020

Volltextzugriff (PDF)

1090P Real-world (RW) clinical outcomes in patients (pts) with locally advanced (LA) or metastatic Merkel cell carcinoma (mMCC) treated in United States (US) oncology clinical practices: Results from SPEAR-Merkel

Annals of oncology, 2020-09, Vol.31, p.S739-S740

2020

Volltextzugriff (PDF)

LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response

Annals of oncology, 2023-10, Vol.34, p.S1288-S1289

2023

Volltextzugriff (PDF)

1089P Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238

Annals of oncology, 2023-10, Vol.34, p.S656-S656

2023

Volltextzugriff (PDF)

843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma

Annals of oncology, 2022-09, Vol.33, p.S934-S935

2022

Volltextzugriff (PDF)

1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238

Annals of oncology, 2020-09, Vol.31, p.S731-S732

2020

Volltextzugriff (PDF)

536MO A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours

Annals of oncology, 2020-09, Vol.31, p.S469-S469

2020

Volltextzugriff (PDF)

Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)

Annals of oncology, 2018-10, Vol.29, p.viii735-viii735

2018

Volltextzugriff (PDF)

LBA68_PR - 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

Annals of oncology, 2019-10, Vol.30, p.v904-v905

2019

Volltextzugriff (PDF)

1310O - Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

Annals of oncology, 2019-10, Vol.30, p.v533-v534

2019

Volltextzugriff (PDF)

5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

Annals of oncology, 2019-10, Vol.30, p.v904-v905

2019

Volltextzugriff (PDF)

A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

Annals of oncology, 2016-10, Vol.27, p.vi393-vi393

2016

Volltextzugriff (PDF)

VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo

Oncogene, 2009-04, Vol.28 (14), p.1694-1705

2009

Volltextzugriff (PDF)

Nivolumab (NIVO) vs ipilimumab (IPI) en traitement adjuvant du mélanome de stade III/IV opéré : résultats de survie sans récidive (SSR) et de survie globale (SG) à 4 ans de l’essai CheckMate 238

Annales de dermatologie et de vénéréologie, 2020-12, Vol.147 (12), p.A78-A79

2020

Volltextzugriff (PDF)

CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL)

Annals of oncology, 2015-10, Vol.26, p.vi28

2015

Volltextzugriff (PDF)

Survie globale avec l’association de nivolumab (NIVO) et d’ipilimumab (IPI) dans un essai de phase III sur le mélanome avancé (CheckMate 067)

Annales de dermatologie et de vénéréologie, 2017-12, Vol.144 (12), p.S256-S257

2017

Volltextzugriff (PDF)

Contrast sensitivity and visual acuity of the pigmented rat determined electrophysiologically

Vision research (Oxford), 1987, Vol.27 (10), p.1719-1731

1987

Volltextzugriff (PDF)

Direct and transcallosal contribution to the cortical visual evoked response in rats

Behavioural brain research, 1989, Vol.31 (3), p.291-294

1989

Volltextzugriff (PDF)

Contrast sensitivity in rats with increased or decreased numbers of retinal ganglion cells

Experimental brain research, 1988-01, Vol.70 (3), p.513-526

1988

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

1029TiP Phase II trial of pembrolizumab (pembro) and brentuximab vedotin (BV) in patients with metastatic solid malignancies after progression on prior programmed cell death protein (PD)-1 inhibitors (SGN35-033)

1116P Real-world clinical outcomes with pembrolizumab (pembro) for treatment of advanced melanoma: Evidence from the United States community oncology setting

1090P Real-world (RW) clinical outcomes in patients (pts) with locally advanced (LA) or metastatic Merkel cell carcinoma (mMCC) treated in United States (US) oncology clinical practices: Results from SPEAR-Merkel

LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response

1089P Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238

843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma

1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238

536MO A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours

Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)

LBA68_PR - 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

1310O - Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo

Nivolumab (NIVO) vs ipilimumab (IPI) en traitement adjuvant du mélanome de stade III/IV opéré : résultats de survie sans récidive (SSR) et de survie globale (SG) à 4 ans de l’essai CheckMate 238

CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL)

Survie globale avec l’association de nivolumab (NIVO) et d’ipilimumab (IPI) dans un essai de phase III sur le mélanome avancé (CheckMate 067)

Contrast sensitivity and visual acuity of the pigmented rat determined electrophysiologically

Direct and transcallosal contribution to the cortical visual evoked response in rats

Contrast sensitivity in rats with increased or decreased numbers of retinal ganglion cells

Suchergebnisse filtern